RxDoctor Payments Data

Aarti Ravikumar

Endocrinology, Diabetes & Metabolism · Bridgewater, NJNPI 1578844007

Payments from drug & device makers

$3,221in general payments, 2019–2025

Across 13 payments — averaging $247.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Abbott$213
  • Dexcom, Inc.$108
  • Otsuka America Pharmaceutical, Inc.$41
  • Boston Scientific$21
  • Cequr Corporation$19
  • plus $30 from 2 others

What the payments were for

  • Consulting fees$2,79087%
  • Food & beverage$43113%

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,221 in reported general payments places this provider in the 60th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$22,071
Medicare patients
51
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$127,880
JardianceEmpagliflozin43$48,223
TrulicityDulaglutide19$38,528
MounjaroTirzepatide33$34,857
TradjentaLinagliptin19$16,671
Humalog Kwikpen U-200Insulin Lispro12$9,362
Humalog Kwikpen U-100Insulin Lispro16$4,856
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$4,725
Icosapent Ethyl12$3,448
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$2,945
Comfort Ez Pen NeedlePen Needle, Diabetic13$2,216
Atorvastatin Calcium59$834
Levothyroxine Sodium78$780
Hydrocortisone14$421
Metformin Hcl ErMetformin Hcl30$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$127,88087 claims
Boehringer IngelheimJardiance, Tradjenta$16$64,89462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →